Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 260

1.

Designing new treatments for depression and anxiety.

Chen Z, Yang J, Tobak A.

IDrugs. 2008 Mar;11(3):189-97. Review.

PMID:
18311656
[PubMed - indexed for MEDLINE]
2.

Triple uptake inhibitors: therapeutic potential in depression and beyond.

Chen Z, Skolnick P.

Expert Opin Investig Drugs. 2007 Sep;16(9):1365-77. Review.

PMID:
17714023
[PubMed - indexed for MEDLINE]
3.

"Broad spectrum" antidepressants: is more better for the treatment of depression?

Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS.

Life Sci. 2003 Nov 7;73(25):3175-9. Review.

PMID:
14561522
[PubMed - indexed for MEDLINE]
4.

Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.

Guiard BP, El Mansari M, Blier P.

Curr Drug Targets. 2009 Nov;10(11):1069-84. Review.

PMID:
19702555
[PubMed - indexed for MEDLINE]
5.

Future antidepressants: what is in the pipeline and what is missing?

Bosker FJ, Westerink BH, Cremers TI, Gerrits M, van der Hart MG, Kuipers SD, van der Pompe G, ter Horst GJ, den Boer JA, Korf J.

CNS Drugs. 2004;18(11):705-32. Review.

PMID:
15330686
[PubMed - indexed for MEDLINE]
6.

2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression.

Carter DS, Cai HY, Lee EK, Iyer PS, Lucas MC, Roetz R, Schoenfeld RC, Weikert RJ.

Bioorg Med Chem Lett. 2010 Jul 1;20(13):3941-5. doi: 10.1016/j.bmcl.2010.05.008. Epub 2010 May 10.

PMID:
20570146
[PubMed - indexed for MEDLINE]
7.

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs.

Millan MJ.

Neurotherapeutics. 2009 Jan;6(1):53-77. doi: 10.1016/j.nurt.2008.10.039. Review.

PMID:
19110199
[PubMed - indexed for MEDLINE]
8.

Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors.

Lee KH, Park CE, Min KH, Shin YJ, Chung CM, Kim HH, Yoon HJ, Won-Kim, Ryu EJ, Shin YJ, Nam HS, Cho JW, Lee HY.

Bioorg Med Chem Lett. 2010 Sep 15;20(18):5567-71. doi: 10.1016/j.bmcl.2010.07.021. Epub 2010 Aug 17.

PMID:
20724153
[PubMed - indexed for MEDLINE]
9.

Monoamine reuptake inhibition and mood-enhancing potential of a specified oregano extract.

Mechan AO, Fowler A, Seifert N, Rieger H, Wöhrle T, Etheve S, Wyss A, Schüler G, Colletto B, Kilpert C, Aston J, Elliott JM, Goralczyk R, Mohajeri MH.

Br J Nutr. 2011 Apr;105(8):1150-63. doi: 10.1017/S0007114510004940. Epub 2010 Dec 21.

PMID:
21205415
[PubMed - indexed for MEDLINE]
10.

Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.

Trivedi MH, Desaiah D, Ossanna MJ, Pritchett YL, Brannan SK, Detke MJ.

Int Clin Psychopharmacol. 2008 May;23(3):161-9. doi: 10.1097/YIC.0b013e3282f41d7e. Review.

PMID:
18408530
[PubMed - indexed for MEDLINE]
11.

Effects of monoamine reuptake inhibitors in assays of acute pain-stimulated and pain-depressed behavior in rats.

Rosenberg MB, Carroll FI, Negus SS.

J Pain. 2013 Mar;14(3):246-59. doi: 10.1016/j.jpain.2012.11.006. Epub 2013 Jan 16.

PMID:
23332494
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

GABAA receptors as targets for novel anxiolytic drugs.

Rupprecht R, Eser D, Zwanzger P, Möller HJ.

World J Biol Psychiatry. 2006;7(4):231-7. Review.

PMID:
17071543
[PubMed - indexed for MEDLINE]
13.

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.

Skolnick P, Krieter P, Tizzano J, Basile A, Popik P, Czobor P, Lippa A.

CNS Drug Rev. 2006 Summer;12(2):123-34. Review.

PMID:
16958986
[PubMed - indexed for MEDLINE]
14.

Differences in mechanism of action between current and future antidepressants.

Stahl SM, Grady MM.

J Clin Psychiatry. 2003;64 Suppl 13:13-7. Review.

PMID:
14552651
[PubMed - indexed for MEDLINE]
15.

Overview of diagnosis and drug treatments of anxiety disorders.

Nutt DJ.

CNS Spectr. 2005 Jan;10(1):49-56. Review.

PMID:
15618947
[PubMed - indexed for MEDLINE]
16.

Recent developments in potential anxiolytic agents targeting GABAA/BzR complex or the translocator protein (18kDa) (TSPO).

Nothdurfter C, Rupprecht R, Rammes G.

Curr Top Med Chem. 2012;12(4):360-70. Review.

PMID:
22204486
[PubMed - indexed for MEDLINE]
17.

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.

Prins J, Olivier B, Korte SM.

Expert Opin Investig Drugs. 2011 Aug;20(8):1107-30. doi: 10.1517/13543784.2011.594039. Epub 2011 Jun 20. Review.

PMID:
21682663
[PubMed - indexed for MEDLINE]
18.

Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs.

Palucha A, Pilc A.

Pharmacol Ther. 2007 Jul;115(1):116-47. Epub 2007 May 13. Review.

PMID:
17582504
[PubMed - indexed for MEDLINE]
19.

Current investigational drugs for major depression.

Kulkarni SK, Dhir A.

Expert Opin Investig Drugs. 2009 Jun;18(6):767-88. doi: 10.1517/13543780902880850 . Review.

PMID:
19426122
[PubMed - indexed for MEDLINE]
20.

New approaches to rapid onset antidepressants.

Briner K, Dodel RC.

Curr Pharm Des. 1998 Aug;4(4):291-302. Review. Erratum in: Curr Pharm Des 1999 Feb;5(2):139.

PMID:
10197044
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk